

PUBLICACIONES DURANT 2013

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.

Sebio A, Paré L, Páez D, Salazar J, González A, Sala N, Del Río E, Martín-Richard M, Tobeña M, Barnadas A, Baiget M.

Pharmacogenet Genomics. 2013 Mar;23

High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.

Téllez-Gabriel M, Arroyo-Solera I, León X, Gallardo A, López M, Céspedes MV, Casanova I, López-Pousa A, Quer M, Mangues MA, Barnadas A, Mangues R, Pavón MA.

Cancer Med. 2013 Dec;2(6):950-63. doi: 10.1002/cam4.153. Epub 2013 Oct 31.

Efficacy of erlotinib in patients with relapsed glioblastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.

Gallego O, Cuatrecasas M, Benavides M, Segura PP, Berrocal A, Erill N, Colomer A, Quintana MJ, Balaña C, Gil M, Gallardo A, Murata P, Barnadas A.

J Neurooncol. 2014 Jan;116(2):413-9. doi: 10.1007/s11060-013-1316-y. Epub 2013 Dec 19.

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.

Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas J, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J.

Invest New Drugs. 2013 Dec;31(6):1573-9.

Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells.

Lasa A, Garcia A, Alonso C, Millet P, Cornet M, Ramón y Cajal T, Baiget M, Barnadas A.

PLoS One. 2013 Sep 18;8(9):e74079. doi: 10.1371/journal.pone.0074079. eCollection 2013.

SEOM clinical guidelines for the systemic treatment of early breast cancer 2013.

Del Barco S, Ciruelos E, Tusquets I, Ruiz M, Barnadas A.

Clin Transl Oncol. 2013 Dec;15(12):1011-7. doi: 10.1007/s12094-013-1084-3. Epub 2013 Aug 27.

Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.

Sebio A, Páez D, Salazar J, Berenguer-Llergo A, Paré-Brunet L, Lasa A, Del Río E, Tobeña M, Martín-Richard M, Baiget M, Barnadas A.

Pharmacogenomics J. 2013 Aug 20. doi: 10.1038/tpj.2013.29. [Epub ahead of print]

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, Margelí Vila M, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Dorca Ribugent J, López-Vega JM, Jara C, Espinosa E, Mendiola Fernández C, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacón JI, Rodríguez CA, Hernando B, Álvarez I, Carrasco E, Lluch A.

J Clin Oncol. 2013 Jul 10;31(20):2593-9. doi: 10.1200/JCO.2012.46.9841. Epub 2013 Jun 3.

A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.

Reynés G, Balañá C, Gallego O, Iglesias L, Pérez P, García JL.

Anticancer Drugs. 2013 Dec 5. [Epub ahead of print]

Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.

Martín-Liberal J, López-Pousa A, Broto JM, Cubedo R, Gallego O, Brendel E, Tirado OM, Del Muro XG.

Invest New Drugs. 2013 Jun 26. [Epub ahead of print]

Detection and characterization of protein interactions in vivo by a simple live-cell imaging method.

Gallego O, Specht T, Brach T, Kumar A, Gavin AC, Kaksonen M.

PLoS One. 2013 May 1;8(5):e62195. doi: 10.1371/journal.pone.0062195. Print 2013.

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.

Ryan CW, Matias C, Agulnik M, Lopez-Pousa A, Williams C, de Alwis DP, Kaiser C, Miller MA, Ermisch S, Ilaria R Jr, Keohan ML.

Invest New Drugs. 2013 Feb;31(1):145-51. doi: 10.1007/s10637-012-9819-5. Epub 2012 Apr 27.

SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013.

Redondo A, Cruz J, Lopez-Pousa A, Barón F.

Clin Transl Oncol. 2013 Dec;15(12):1037-43. doi: 10.1007/s12094-013-1087-0. Epub 2013 Aug 2.

[Primary, non-metastatic gastrointestinal stromal tumour surgery: results of the GRISK study].

Artigas Raventós V, López Pousa A, Ortega Medina L, Díaz de Liaño Argüelles A, Fernández Hernández JÁ, Lucena de la Poza JL.

Cir Esp. 2013 Feb;91(2):96-102. doi: 10.1016/j.ciresp.2012.05.002. Epub 2012 Jun 28. Spanish.

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.

Ryan CW, Matias C, Agulnik M, Lopez-Pousa A, Williams C, de Alwis DP, Kaiser C, Miller MA, Ermisch S, Ilaria R Jr, Keohan ML.

Invest New Drugs. 2013 Feb;31(1):145-51. doi: 10.1007/s10637-012-9819-5. Epub 2012 Apr 27.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Ann Oncol. 2014 Jan;25(1):216-25. doi: 10.1093/annonc/mdt461. Epub 2013 Nov 19.

MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study.

Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez-Serra A, Lopez-Pousa A, Gronchi A.

Mol Cancer Ther. 2014 Jan;13(1):249-59. doi: 10.1158/1535-7163.MCT-13-0406. Epub 2013 Oct 21.

Lung cancer in women: an overview with special focus on Spanish women.

Remon J, Molina-Montes E, Majem M, Lianes P, Isla D, Garrido P, Felip E, Viñolas N, de Castro J, Artal A, Sánchez MJ.

Clin Transl Oncol. 2013 Nov 26.

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.

Bonanno L, Costa C, Majem M, Sanchez JJ, Gimenez-Capitan A, Rodriguez I, Vergnenegre A, Massuti B, Favaretto A, Ruge M, Pallares C, Taron M, Rosell R.

Oncotarget. 2013 Oct;4

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.

Remon J, Morán T, Majem M, Reguart N, Dalmau E, Márquez-Medina D, Lianes P.

Cancer Treat Rev. 2014 Feb;40(1):93-101. doi: 10.1016/j.ctrv.2013.06.002. Epub 2013 Jul 3. Review.

The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.

Bonanno L, Costa C, Majem M, Favaretto A, Ruge M, Rosell R.

Ann Oncol. 2013 Apr;24(4):1130-2. doi: 10.1093/annonc/mdt063. Epub 2013 Feb 20.

BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.

Karachaliou N, Costa C, Gimenez-Capitan A, Molina-Vila MA, Bertran-Alamillo J, Mayo C, Massuti B, Majem M, Carcereny E, Moran T, Sanchez JJ, Viteri S, Gasco A, Wannesson L, Souglakos J, Jimeno J, Rosell R; Spanish Lung Cancer Group.

J Thorac Oncol. 2013 Mar;8

An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.

Majem M, Pallarès C.

Clin Transl Oncol. 2013 May;15(5):343-57. doi: 10.1007/s12094-012-0964-2. Epub 2013 Jan 29. Review.

Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.

Gallardo E, Arranz JÁ, Maroto JP, León LÁ, Bellmunt J.

Crit Rev Oncol Hematol. 2013 Nov;88(2):357-67. doi: 10.1016/j.critrevonc.2013.06.008. Epub 2013 Jul 16.

Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).

Maroto JP, del Muro XG, Mellado B, Perez-Gracia JL, Andrés R, Cruz J, Gallardo E, Domenech M, Arranz JA, Meana JA.

Clin Transl Oncol. 2013 Sep;15(9):698-704. doi: 10.1007/s12094-012-0991-z. Epub 2013 Jan 29.

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.

Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas J, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J.

Invest New Drugs. 2013 Dec;31(6):1573-9.

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.

Martín-Richard M, Massutí B, Pineda E, Alonso V, Marmol M, Castellano D, Fonseca E, Galán A, Llanos M, Sala MA, Pericay C, Rivera F, Sastre J, Segura A, Quindós M, Maisonobe P; TTD (Tumores del Tracto Digestivo) Study Group.

BMC Cancer. 2013 Sep 20;13:427. doi: 10.1186/1471-2407-13-427.

Lytic lesions in a patient with past history of renal cancer.

Sebio A, Robert L, Ovejero D, Murata P, Sullivan I, Stradella A, Maroto P.

Arch Esp Urol. 2013 Apr;66(3):302-4.

Association of common gene variants in the WNT/ β -catenin pathway with colon cancer recurrence.

Páez D, Gerger A, Zhang W, Yang D, Labonte MJ, Benhaim L, Kahn M, Lenz F, Lenz C, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ.

Pharmacogenomics J. 2013 Jul 2.

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.

Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y, El-Khoueiry R, Loupakis F, Zhang W, Laurent-Puig P, Lenz HJ.

Pharmacogenomics J. 2013 Jun 11.

Pharmacogenetic analysis in the treatment of Hodgkin lymphoma.

Altés A, Paré L, Esquirol A, Xicoy B, Rámila E, Vicente L, López R, Orriols J, Vall-llovera F, Sánchez-González B, del Río E, Sureda A, Páez D, Baiget M.

Leuk Lymphoma. 2013 Aug;54(8):1706-12. doi: 10.3109/10428194.2012.752080. Epub 2013 Feb 1.

About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.

Gutiérrez-Enríquez S, Bonache S, Ruíz de Garibay G, Osorio A, Santamariña M, Ramón y Cajal T, Esteban-Cardenosa E, Tenés A, Yanowsky K, Barroso A, Montalban G, Blanco A, Cornet M, Gadea N, Infante M, Caldés T, Díaz-Rubio E, Balmaña J, Lasa A, Vega A, Benítez J, de la Hoya M, Diez O.

Int J Cancer. 2013 Oct 15. doi: 10.1002/ijc.28540.

Evaluation of rare variants in the new fanconi anemia gene ERCC4 (FANCF) as familial breast/ovarian cancer susceptibility alleles.

Osorio A, Bogliolo M, Fernández V, Barroso A, de la Hoya M, Caldés T, Lasa A, Ramón y Cajal T, Santamariña M, Vega A, Quiles F, Lázaro C, Díez O, Fernández D, González-Sarmiento R, Durán M, Piqueras JF, Marín M, Pujol R, Surrallés J, Benítez J.

Hum Mutat. 2013 Dec;34(12):1615-8. doi: 10.1002/humu.22438. Epub 2013 Oct 7.

Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).

Andrés R, Pajares I, Balmaña J, Lloret G, Ramón Y Cajal T, Chirivella I, Aguirre E, Robles L, Lastra E, Pérez-Segura P, Bosch N, Yagüe C, Lerma E, Godino J, Miramar MD, Moros M, Astier P, Saez B, Vidal MJ, Arcusa A, Ramón Y Cajal S, Calvo MT, Tres A.

Clin Transl Oncol. 2013 Aug 27.

DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.

Kamieniak MM, Muñoz-Repeto I, Rico D, Osorio A, Urioste M, García-Donas J, Hernando S, Robles-Díaz L, Ramón y Cajal T, Cazorla A, Sáez R, García-Bueno JM, Domingo S, Borrego S, Palacios J, van de Wiel MA, Ylstra B, Benítez J, García MJ.

Br J Cancer. 2013 Apr 30;108(8):1732-42. doi: 10.1038/bjc.2013.141. Epub 2013 Apr 4.

Identification of a founder EPCAM deletion in Spanish Lynch syndrome families.

Mur P, Pineda M, Romero A, Del Valle J, Borràs E, Canal A, Navarro M, Brunet J, Rueda D, Ramón y Cajal T, Lázaro C, Caldés T, Blanco I, Soto J, Capellá G.

Clin Genet. 2013 Mar 26. doi: 10.1111/cge.12152. [Epub ahead of print]

BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.

Grotsky DA, Gonzalez-Suarez I, Novell A, Neumann MA, Yaddanapudi SC, Croke M, Martinez-Alonso M, Redwood AB, Ortega-Martinez S, Feng Z, Lerma E, Ramon y Cajal T, Zhang J, Matias-Guiu X, Dusso A, Gonzalo S.

J Cell Biol. 2013 Jan 21;200(2):187-202. doi: 10.1083/jcb.201204053.

Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.

Muñoz-Repeto I, García MJ, Kamieniak M, Ramón Y Cajal T, Domingo S, Cazorla A, García Donas J, Hernando Polo S, García Sagredo JM, Hernández E, Lacambra C, Saez R, Robles L, Borrego S, Prat J, Palacios J, Benítez J.

Histol Histopathol. 2013 Jan;28(1):133-44.